echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Menarini receives FDA orphan drug designation for acute myeloid leukemia drug

    Menarini receives FDA orphan drug designation for acute myeloid leukemia drug

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Florence, Italy, November 5, 2021/PRNewswire/ - Menarini Group today announced that the U.


    ODD is awarded by the FDA to therapies designed to treat diseases that affect less than 200,000 people in the United States, and provides companies with multiple incentives to support the development of treatment and diagnosis of rare diseases


    Elcin Barker Ergun, Chief Executive Officer of Menarini Group, said: "The FDA orphan drug qualification is an important milestone in the SEL24/MEN1703 program


    DIAMOND-01 (CLI24-001; clinicaltrials.


    In the dose upgrade part of the DIAMOND-01 trial, SEL24/MEN1703 demonstrated the controllable safety of the maximum recommended dose (RD) of 125 mg/day and preliminary evidence of anti-leukemia activity as a single agent


    This trial is currently recruiting AML patients with IDH1 or IDH2 mutations to further study the viability of SEL24/MEN1703 in this molecularly determined subgroup of patients


    About SEL24/MEN1703 

    SEL24/MEN1703 is a first-of-its-kind oral dual PIM/FLT3 inhibitor, which is licensed internally by Menarini from Ryvu Therapeutics


    About Menarini's Oncology Work 

    At Menarini, we recognize that patients’ hopes for longer and healthier lives are inseparably connected with the progress of scientific and medical research-this is the driving force behind our progress


    Menarini Group has a firm commitment to oncology research and development, while focusing on treatment and diagnosis


    The 2020 acquisition of Stemline Therapeutics, a New York biopharmaceutical company, marks Menarini Group’s entry into the US biopharmaceutical oncology market.


    For more information about the Menarini project, please visit a dedicated page on our website: https:// Menarini 

    Menarini Group is a leading international pharmaceutical and diagnostic company with more than 17,000 employees and a turnover of 4.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.